A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Levothyroxine (ERMEZA)

Levothyroxine replaces or supplements thyroid hormone in patients with hypothyroidism.

First FDA approval2001-05-25
Generic availableNo (brand-only)
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.037/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.037
Across all dosage forms in distribution.
Highest NADAC
$0.037
Range is tight.
Plans with PA
15 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Levothyroxine used for?

Levothyroxine replaces or supplements thyroid hormone in patients with hypothyroidism.

Is there a generic for Levothyroxine?

No. Levothyroxine is brand-only with no generic equivalents currently in market.

How much does my plan pay for Levothyroxine?

Across 329 Part D plans, Levothyroxine averages $0.037/unit (NADAC). Lowest available: $0.037/unit. Highest in distribution: $0.037/unit.

Is Levothyroxine on the FDA shortage list?

Levothyroxine has been discontinued by its manufacturer(s).

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Thyroid Hormone1 alternative in D1
01
Liothyronine
Brand: Cytomel
$0.209Lowest NADAC
7Generic mfrs
$43.1MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.